Search

Your search keyword '"Diaz-Rubio, E."' showing total 409 results
Start Over Author "Diaz-Rubio, E."
409 results on '"Diaz-Rubio, E."'

1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

Author

Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., and Aranda, E.

Published
2023
Full Text
View/download PDF

2. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and

Author

Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P., Cano, M.T., Reina-Zoilo, J.J., Salud-Salvia, A., Robles-Díaz, L., Gil, S., Asensio-Martínez, E., García-Paredes, B., López, R.L., Valladares-Ayerbes, M., Aranda, E., and Díaz-Rubio, E.

Published
2021
Full Text
View/download PDF

4. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Author

Aranda, E., García-Alfonso, P., Benavides, M., Sánchez Ruiz, A., Guillén-Ponce, C., Safont, M.J., Alcaide, J., Gómez, A., López, R., Manzano, J.L., Méndez Ureña, M., Sastre, J., Rivera, F., Grávalos, C., García, T., Martín-Valadés, J.I., Falcó, E., Navalón, M., González Flores, E., M<ce:sup loc='post">a</ce:sup> García Tapiador, A., M<ce:sup loc='post">a</ce:sup> López Muñoz, A., Barrajón, E., Reboredo, M., García Teijido, P., Viudez, A., Cárdenas, N., and Díaz-Rubio, E.

Published
2018
Full Text
View/download PDF

10. Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation

Author

Ramirez, P., Sáenz, L., Cascales-Campos, P.A., González Sánchez, M.R., Llàcer-Millán, E., Sánchez-Lorencio, M.I., Díaz-Rubio, E., De La Orden, V., Mediero-Valeros, B., Navarro, J.L., Revilla Nuin, B., Baroja-Mazo, A., Noguera-Velasco, J.A., Sánchez, B.F., de la Peña, J., Pons-Miñano, J.A., Sánchez-Bueno, F., Robles-Campos, R., and Parrilla, P.

Published
2016
Full Text
View/download PDF

11. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Author

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., and Arnold, D.

Published
2016
Full Text
View/download PDF

13. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

Author

Sastre, J., Massuti, B., Pulido, G., Guillén-Ponce, C., Benavides, M., Manzano, J.L., Reboredo, M., Rivera, F., Grávalos, C., Safont, M.J., Martínez Villacampa, M., Llovet, P., Dotor, E., Díaz-Rubio, E., and Aranda, E.

Published
2015
Full Text
View/download PDF

22. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Author

Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez M, Sastre J, Alonso-Orduna V, Vieitez J, Yubero A, Vera R, Asensio-Martinez E, Garcia-Alfonso P, Aranda E, Diaz-Rubio E, and Perez-Villamil B

Subjects
stage III, microsatellite instability, microRNAs expression, Colorectal cancer, survival, prognostic biomarkers
Abstract

BACKGROUND: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors. OBJECTIVE: To confirm in stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease. To correlate miR expression with microsatellite instability (MSI) and mutations in RAS and BRAF. METHODS: miR-21, miR-135a, miR-206, miR-335 and miR-Let-7a expression was analyzed by RT-qPCR in 150 patients out of the 329 patients used to analyze MSI and RAS and BRAF mutations. Association with disease free survival (DFS) and overall survival (OS) was analyzed. Data was confirmed by a multivariate analysis. RESULTS: MiR-21 high expression ( p = 0.034) and miR-335 low expression ( p = 0.0061) were significantly associated with MSI-H. A positive trend (p = 0.0624) between miR-135a high expression and RAS mutations was found. Lower miR-21 expression levels are associated with DFS (HR = 2.654, 95% CI: 1.066-6.605, p = 0.036) and a trend with OS (HR = 2.419, 95% CI: 0.749-7.815, p = 0.140). MiR-21 high expression significantly improves DFS of the poor prognosis group (T4 or N2) (p = 0.03). CONCLUSIONS: Association of increased expression of miR-21 and better prognosis in the poor prognostic group may be of interest and could be explored in future prospective clinical trials.

Published
2022

23. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Author

Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez C, Vieitez J, Rivera F, Safont M, Abad A, Sastre J, Valladares-Ayerbes M, Carrato A, Gonzalez-Flores E, Robles L, Salud A, Alonso-Orduna V, Montagut C, Asensio E, Diaz-Rubio E, and Aranda E

Subjects
Targeted therapy, Retrospective, Sidedness, Upfront primary tumour resection, Synchronous unresectable metastasis, RAS
Abstract

Introduction: Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus of its role in routine clinical practice in the current era of targeted therapies is lacking. This retrospective study aimed to analyse the survival benefit of UPTR in terms of tumour location and mutational status, in patients with synchronous mCRC receiving chemotherapy and targeted therapy. Patients and methods: Survival was analysed in a pooled cohort of synchronous mCRC patients treated with a first-line anti-VEGF or anti-EGFR inhibitor in seven trials of the Spanish TTD group, according to UPTR, tumour-sidedness and mutational profiling. Results: Of 1334 eligible patients, 642 (48%) had undergone UPTR. UPTR was associated with significantly longer overall survival (OS; 25.0 vs 20.3 months; HR 1.30, 95%CI 1.15-1.48; p < 0.0001). UPTR was associated with significant OS benefit in both left-sided (HR 1.38, 95%CI 1.13-1.69; p = 0.002) and right-sided (HR 1.39, 95%CI 1.00-1.94; p = 0.049) tumours, RASwt (HR 1.29, 95%CI 1.05-1.60; p = 0.016) and BRAFwt (HR 1.49, 95%CI 1.21-1.84; p = 0.0002) tumours, and treatment with anti-EGFRs (HR 1.47, 95%CI 1.13-1.92; p = 0.004) and anti-VEGFs (HR 1.25, 95%CI 1.08-1.44; p = 0.003). Multivariate analysis identified number of metastatic sites, RAS status, primary tumour location and UPTR as independent prognostic factors for OS. Conclusion: Considering the selection bias inherent to this study, our results support UPTR before first-line anti-EGFR or anti-VEGF targeted therapy in right and left-sided asymptomatic unresectable synchronous mCRC patients. RAS/BRAF mutational status may also influence UPTR function. (C) 2021 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Published
2022

25. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Author

Van Cutsem, E., Dicato, M., Arber, N., Berlin, J., Cervantes, A., Ciardiello, F., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Geva, R., Glimelius, B., Jones, R. Glynne, Grothey, A., Gruenberger, T., Haller, D., Haustermans, K., Labianca, R., Lenz, H.J., Minsky, B., Nordlinger, B., Ohtsu, A., Pavlidis, N., Rougier, P., Schmiegel, W., Van de Velde, C., Schmoll, H.J., Sobrero, A., and Tabernero, J.

Published
2010
Full Text
View/download PDF

27. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Author

Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J.D., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Gruenberger, T., Haller, D., Haustermans, K., Hoff, P., Kerr, D., Labianca, R., Moore, M., Nordlinger, B., Ohtsu, A., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., and van de Velde, C.

Published
2009
Full Text
View/download PDF

28. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Author

Aranda, E., Valladares, M., Martinez-Villacampa, M., Benavides, M., Gomez, A., Massutti, B., Marcuello, E., Constenla, M., Cámara, J.C., Carrato, A., Dueñas, R., Reboredo, M., Navarro, M., and Díaz-Rubio, E.

Published
2009
Full Text
View/download PDF

31. Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Author

Benavides M, Gomez-Espana A, Garcia-Alfonso P, Garcia C, Vieitez J, Sureda B, Rivera F, Aguilera M, Esteve A, Ortega M, Valladares-Ayerbes M, Mena A, Gonzalez-Flores E, Robles L, Salvia A, Alonso V, Viladot C, Asensio-Martinez E, Diaz-Rubio E, and Aguilar E

Published
2021

32. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Author

Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, and Spanish Cooperative Grp Treatment

Abstract

Background Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective This study was undertaken to compare the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods This retrospective analysis used pooled data from five trials undertaken by the Spanish Cooperative Group for the Treatment of Digestive Tumours. All were studies of adults with advanced CRC who received first-line treatment with chemotherapy plus bevacizumab, cetuximab or panitumumab, stratified by age (>= 65 vs. < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results In total, 999 patients from five studies were included in the analysis: 480 (48%) were aged >= 65 years, and 519 (52%) were aged < 65 years. Median PFS did not differ significantly between patients aged >= 65 and < 65 years (9.9 vs. 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88-1.17). Median OS was significantly shorter in older than in younger patients (21.3 vs. 25.0 months; HR 1.21; 95% CI 1.04-1.41). There was no significant difference between older and younger patients in ORR (59 vs. 62%). Patients aged >= 65 years experienced significantly more treatment-related grade 3 or higher adverse events (61.67%) than did patients aged < 65 years (45.86%). Conclusions Biologicals plus chemotherapy is an effective first-line treatment option for selected patients aged >= 65 years with mCRC and has a manageable safety profile and efficacy comparable to that observed in younger patients.

Published
2021

33. Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon

Author

Martin-Moreno J, Ruiz-Segovia N, and Diaz-Rubio E

Abstract

Traditionally, the prevention of cancer (and other chronic diseases) has been considered primarily linked to personal responsibility, for which interventions must be based on health education information enabling individuals to make knowledge-based decisions to improve their lifestyle. However, lifestyle is conditioned by environmental factors (including dimensions such as the context of economics, transport, urbanism, agriculture, or education) that may render healthy behavioural choices either easier or impossible. This article reviews the conceptual underpinnings of the behaviour-structural dichotomy. We believe that it is advisable to opt for multilevel strategies that take into account all the determinants of health, using structural and behavioural approaches, rather than only the latter as has been done until now. This article is protected by copyright. All rights reserved.

Published
2021

34. P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials

Author

Valladares-Ayerbes, M., primary, Toledano Fonseca, M., additional, Vieitez de Prado, J., additional, Inga-Saavedra, E., additional, Gil, S., additional, Graña Suarez, B., additional, García-Paredes, B., additional, Salud, A., additional, Rivera Herrero, F., additional, Salgado Fernandez, M., additional, García-Alfonso, P., additional, López-López, R., additional, Ferreiro Monteagudo, R., additional, Sastre, J., additional, Diaz-Rubio, E., additional, and Aranda, E., additional

Published
2021
Full Text
View/download PDF

35. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.

Author

Yin, J, Dawood, S, Cohen, R, Meyers, J, Zalcberg, J, Yoshino, T, Seymour, M, Maughan, T, Saltz, L, Van Cutsem, E, Venook, A, Schmoll, H-J, Goldberg, R, Hoff, P, Hecht, JR, Hurwitz, H, Punt, C, Diaz Rubio, E, Koopman, M, Cremolini, C, Heinemann, V, Tournigard, C, Bokemeyer, C, Fuchs, C, Tebbutt, N, Souglakos, J, Doulliard, J-Y, Kabbinavar, F, Chibaudel, B, de Gramont, A, Shi, Q, Grothey, A, Adams, R, Yin, J, Dawood, S, Cohen, R, Meyers, J, Zalcberg, J, Yoshino, T, Seymour, M, Maughan, T, Saltz, L, Van Cutsem, E, Venook, A, Schmoll, H-J, Goldberg, R, Hoff, P, Hecht, JR, Hurwitz, H, Punt, C, Diaz Rubio, E, Koopman, M, Cremolini, C, Heinemann, V, Tournigard, C, Bokemeyer, C, Fuchs, C, Tebbutt, N, Souglakos, J, Doulliard, J-Y, Kabbinavar, F, Chibaudel, B, de Gramont, A, Shi, Q, Grothey, A, and Adams, R

Abstract

BACKGROUND: Benchmarking international cancer survival differences is necessary to evaluate and improve healthcare systems. Our aim was to assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) participating in international randomized clinical trials (RCTs). DESIGN: Countries were grouped into 11 regions according to the World Health Organization and the EUROCARE model. Meta-analyses based on individual patient data were used to synthesize data across studies and regions and to conduct comparisons for outcomes in a two-stage random-effects model after adjusting for age, sex, performance status, and time period. We used mCRC patients enrolled in the first-line RCTs from the ARCAD database, which provided enrolling country information. There were 21,509 patients in 27 RCTs included across the 11 regions. RESULTS: Main outcomes were overall survival (OS) and progression-free survival (PFS). Compared with other regions, patients from the United Kingdom (UK) and Ireland were proportionaly over-represented, older, with higher performance status, more frequently male, and more commonly not treated with biological therapies. Cohorts from central Europe and the United States (USA) had significantly longer OS compared with those from UK and Ireland (p = 0.0034 and p < 0.001, respectively), with median difference of 3-4 months. The survival deficits in the UK and Ireland cohorts were, at most, 15% at 1 year. No evidence of a regional disparity was observed for PFS. Among those treated without biological therapies, patients from the UK and Ireland had shorter OS than central Europe patients (p < 0.001). CONCLUSIONS: Significant international disparities in the OS of cohorts of mCRC patients enrolled in RCTs were found. Survival of mCRC patients included in RCTs was consistently lower in the UK and Ireland regions than in central Europe, southern Europe, and the USA, potentially attributed to greater overall population repr

Published
2021

36. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Author

Van Cutsem, E., Dicato, M., Geva, R., Arber, N., Bang, Y., Benson, A., Cervantes, A., Diaz-Rubio, E., Ducreux, M., Glynne-Jones, R., Grothey, A., Haller, D., Haustermans, K., Kerr, D., Nordlinger, B., Marshall, J., Minsky, B. D., Kang, Y. K., Labianca, R., Lordick, F., Ohtsu, A., Pavlidis, N., Roth, A., Rougier, P., Schmoll, H. J., Sobrero, A., Tabernero, J., Van de Velde, C., and Zalcberg, J.

Published
2011
Full Text
View/download PDF

39. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

Author

Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J.-F, Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y.-K., Kerr, D., Labianca, R., Minsky, B. D., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., and Zalcberg, J.

Published
2008

40. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Author

Franko, J, Shi, Q, Meyers, J, Maughan, T, Adams, R, Seymour, M, Saltz, L, Punt, C, Koopman, M, Tournigand, C, Tebbutt, N, Diaz-Rubio, E, Souglakos, J, Falcone, A, Chibaudel, B, Heinemann, V, Moen, J, De Gramont, A, Sargent, D, Grothey, A, Group, Analysis And Research In Cancers Of The Digestive System (Arcad), and Oncology

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Colorectal cancer, Clinical Trial, Phase III, Rectum, Metastasis, law.invention, 03 medical and health sciences, Phase III, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Journal Article, medicine, Clinical endpoint, Humans, Prospective Studies, Prospective cohort study, Peritoneal Neoplasms, Aged, Proportional Hazards Models, Aged, 80 and over, Proportional hazards model, business.industry, Middle Aged, Prognosis, medicine.disease, Clinical Trial, Clinical trial, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Randomized Controlled Trial, Female, 030211 gastroenterology & hepatology, Colorectal Neoplasms, business
Abstract

BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included if protocols explicitly pre-specified and solicited for patients with peritoneal involvement in the trial data collection process or had done a formal peritoneum-focused review of individual pre-treatment scans. We used stratified multivariable Cox models to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival, adjusting for other key clinical-pathological factors (age, sex, Eastern Cooperative Oncology Group (ECOG) performance score, primary tumour location [colon vs rectum], previous treatment, and baseline BMI). The primary endpoint was difference in overall survival between populations with and without peritoneal metastases. FINDINGS: Individual patient data were available for 10 553 patients. 9178 (87%) of 10 553 patients had non-peritoneal metastatic colorectal cancer (4385 with one site of metastasis, 4793 with two or more sites of metastasis), 194 (2%) patients had isolated peritoneal metastatic colorectal cancer, and 1181 (11%) had peritoneal metastatic colorectal cancer and other organ involvement. These groups were similar in age, ethnic origin, and use of targeted treatment. Patients with peritoneal metastatic colorectal cancer were more likely than those with non-peritoneal metastatic colorectal cancer to be women (565 [41%] of 1371 vs 3312 [36%] of 9169 patients; p=0·0003), have colon primary tumours (1116 [84%] of 1334 patients vs 5603 [66%]; p

Published
2019
Full Text
View/download PDF

42. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

Author

Verslype, C., Van Cutsem, E., Dicato, M., Cascinu, S., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Haustermans, K., Heinemann, V., Hoff, P., Johnston, P. G., Kerr, D., Labianca, R., Louvet, C., Minsky, B., Moore, M., Nordlinger, B., Pedrazzoli, S., Roth, A., Rothenberg, M., Rougier, P., Schmoll, H.-J., Tabernero, J., Tempero, M., van de Velde, C., Van Laethem, J.-L., and Zalcberg, J.

Published
2007

43. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005

Author

Van Cutsem, E., Dicato, M., Arber, N., Benson, A., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Goldberg, R., Haller, D., Haustermans, K., Koo-Kang, Y., Labianca, R., Lang, I., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H.-J., Sobrero, A., Tabernero, J., Szawlowski, A., and van de Velde, C.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results